DAY
13
Liposomal Amphotericin B initiated*
following renal decline
Mustafa responded well to treatment with Liposomal
Amphotericin B and flucytosine, with resolution of his
fever, and he reported that the severity of his headache
had reduced.*,**
*Please refer to the Summary of Product Characteristics of your chosen treatment prior to prescribing.
**No evidence of benefit from the use of flucytosine with Liposomal Amphotericin B has been observed.
Whilst synergy between amphotericin and flucytosine has been reported, concurrent use may increase the
toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.1
After one week of induction therapy with
Liposomal Amphotericin B, his treatment was
changed to fluconazole (800 mg/day) for a total of
10 weeks. Fluconazole was then continued at a
reduced dose (200 mg/day) until Somchai's CD4+
count had increased and his risk of infection was
lowered.
Why Liposomal Amphotericin B
Mustafa's outcome
DAY
13
Resolution of symptoms
Mustafa responded well to treatment with Liposomal Amphotericin B and flucytosine, with resolution of his fever, and he
reported that the severity of his headache had reduced.*,**
After one week of induction therapy with Liposomal Amphotericin B, his treatment was changed to fluconazole (800 mg/day) for a
total of 10 weeks. Fluconazole was then continued at a reduced dose (200 mg/day) until Somchai's CD4+ count had increased
and his risk of infection was lowered.
*Please refer to the Summary of Product Characteristics of your chosen treatment prior to prescribing.
**No evidence of benefit from the use of flucytosine with Liposomal Amphotericin B has been observed. Whilst synergy between amphotericin and flucytosine has been reported, concurrent use may
increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.1
Why Liposomal Amphotericin B
Mustafa's outcome